Forum · Medicine · Story discussion
Novel Oral HAE Drug Measures Up to Injectable Options
(MedPage Today) -- Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed. For the primary…
2.9 hours ago — MedPage Today · Read the original
Peer reviews (0)
Comments (0)
No comments yet. Start the discussion.
Loading sign-in…